Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency

Joseph A. Church, Heinz Leibl, Mark R. Stein, Isaac R. Melamed, Arye Rubinstein, Lynda C. Schneider, Richard L. Wasserman, Borislava G. Pavlova, Karl Birthistle, Marianne Mancini, Sandor Fritsch, Lisa Patrone, Kerry Moore-Perry, Hartmut J. Ehrlich, Joseph A. Church, Linda B. Ford, Roger H. Kobayashi, Dennis K. Ledford, Issac R. Melamed, James N. MoyArye Rubinstein, Lynda C. Schneider, Mark R. Stein, Dale T. Umetsu, Richard L. Wasserman

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300-600 mg/kg body weight every 21-28 days for 12 months. No validated acute serious bacterial infections were reported. The 95% confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0-0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9% of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10% liquid intravenous imunoglobulin preparation.

Original languageEnglish (US)
Pages (from-to)388-395
Number of pages8
JournalJournal of Clinical Immunology
Volume26
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Intravenous Immunoglobulins
Bacterial Infections
Safety
Immunoglobulin G
Deficiency Diseases
Headache
Half-Life
Hospitalization
Pharmacokinetics
Body Weight
Confidence Intervals

Keywords

  • Efficacy
  • IGIV
  • Immune globulin
  • Pharmacokinetics
  • Primary immunodeficiency
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. / Church, Joseph A.; Leibl, Heinz; Stein, Mark R.; Melamed, Isaac R.; Rubinstein, Arye; Schneider, Lynda C.; Wasserman, Richard L.; Pavlova, Borislava G.; Birthistle, Karl; Mancini, Marianne; Fritsch, Sandor; Patrone, Lisa; Moore-Perry, Kerry; Ehrlich, Hartmut J.; Church, Joseph A.; Ford, Linda B.; Kobayashi, Roger H.; Ledford, Dennis K.; Melamed, Issac R.; Moy, James N.; Rubinstein, Arye; Schneider, Lynda C.; Stein, Mark R.; Umetsu, Dale T.; Wasserman, Richard L.

In: Journal of Clinical Immunology, Vol. 26, No. 4, 07.2006, p. 388-395.

Research output: Contribution to journalArticle

Church, JA, Leibl, H, Stein, MR, Melamed, IR, Rubinstein, A, Schneider, LC, Wasserman, RL, Pavlova, BG, Birthistle, K, Mancini, M, Fritsch, S, Patrone, L, Moore-Perry, K, Ehrlich, HJ, Church, JA, Ford, LB, Kobayashi, RH, Ledford, DK, Melamed, IR, Moy, JN, Rubinstein, A, Schneider, LC, Stein, MR, Umetsu, DT & Wasserman, RL 2006, 'Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency', Journal of Clinical Immunology, vol. 26, no. 4, pp. 388-395. https://doi.org/10.1007/s10875-006-9025-3
Church, Joseph A. ; Leibl, Heinz ; Stein, Mark R. ; Melamed, Isaac R. ; Rubinstein, Arye ; Schneider, Lynda C. ; Wasserman, Richard L. ; Pavlova, Borislava G. ; Birthistle, Karl ; Mancini, Marianne ; Fritsch, Sandor ; Patrone, Lisa ; Moore-Perry, Kerry ; Ehrlich, Hartmut J. ; Church, Joseph A. ; Ford, Linda B. ; Kobayashi, Roger H. ; Ledford, Dennis K. ; Melamed, Issac R. ; Moy, James N. ; Rubinstein, Arye ; Schneider, Lynda C. ; Stein, Mark R. ; Umetsu, Dale T. ; Wasserman, Richard L. / Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. In: Journal of Clinical Immunology. 2006 ; Vol. 26, No. 4. pp. 388-395.
@article{1ddb8b1894c749d489024b3b8ceff708,
title = "Efficacy, safety and tolerability of a new 10{\%} liquid intravenous immune globulin [IGIV 10{\%}] in patients with primary immunodeficiency",
abstract = "The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10{\%} liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300-600 mg/kg body weight every 21-28 days for 12 months. No validated acute serious bacterial infections were reported. The 95{\%} confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0-0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9{\%} of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10{\%} liquid intravenous imunoglobulin preparation.",
keywords = "Efficacy, IGIV, Immune globulin, Pharmacokinetics, Primary immunodeficiency, Safety",
author = "Church, {Joseph A.} and Heinz Leibl and Stein, {Mark R.} and Melamed, {Isaac R.} and Arye Rubinstein and Schneider, {Lynda C.} and Wasserman, {Richard L.} and Pavlova, {Borislava G.} and Karl Birthistle and Marianne Mancini and Sandor Fritsch and Lisa Patrone and Kerry Moore-Perry and Ehrlich, {Hartmut J.} and Church, {Joseph A.} and Ford, {Linda B.} and Kobayashi, {Roger H.} and Ledford, {Dennis K.} and Melamed, {Issac R.} and Moy, {James N.} and Arye Rubinstein and Schneider, {Lynda C.} and Stein, {Mark R.} and Umetsu, {Dale T.} and Wasserman, {Richard L.}",
year = "2006",
month = "7",
doi = "10.1007/s10875-006-9025-3",
language = "English (US)",
volume = "26",
pages = "388--395",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency

AU - Church, Joseph A.

AU - Leibl, Heinz

AU - Stein, Mark R.

AU - Melamed, Isaac R.

AU - Rubinstein, Arye

AU - Schneider, Lynda C.

AU - Wasserman, Richard L.

AU - Pavlova, Borislava G.

AU - Birthistle, Karl

AU - Mancini, Marianne

AU - Fritsch, Sandor

AU - Patrone, Lisa

AU - Moore-Perry, Kerry

AU - Ehrlich, Hartmut J.

AU - Church, Joseph A.

AU - Ford, Linda B.

AU - Kobayashi, Roger H.

AU - Ledford, Dennis K.

AU - Melamed, Issac R.

AU - Moy, James N.

AU - Rubinstein, Arye

AU - Schneider, Lynda C.

AU - Stein, Mark R.

AU - Umetsu, Dale T.

AU - Wasserman, Richard L.

PY - 2006/7

Y1 - 2006/7

N2 - The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300-600 mg/kg body weight every 21-28 days for 12 months. No validated acute serious bacterial infections were reported. The 95% confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0-0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9% of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10% liquid intravenous imunoglobulin preparation.

AB - The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300-600 mg/kg body weight every 21-28 days for 12 months. No validated acute serious bacterial infections were reported. The 95% confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0-0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9% of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10% liquid intravenous imunoglobulin preparation.

KW - Efficacy

KW - IGIV

KW - Immune globulin

KW - Pharmacokinetics

KW - Primary immunodeficiency

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=33745877615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745877615&partnerID=8YFLogxK

U2 - 10.1007/s10875-006-9025-3

DO - 10.1007/s10875-006-9025-3

M3 - Article

C2 - 16705486

AN - SCOPUS:33745877615

VL - 26

SP - 388

EP - 395

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 4

ER -